Outcomes after corneal crosslinking treatment in paediatric patients with keratoconus

Basit Öğe Kaydı
dc.authorwosidCankaya, Cem/HTR-3803-2023
dc.contributor.authorCankaya, Cem
dc.contributor.authorGungor, Nur
dc.date.accessioned2024-08-04T20:55:05Z
dc.date.available2024-08-04T20:55:05Z
dc.date.issued2024
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurposeThis study aims to determine the efficacy and safety of accelerated corneal crosslinking in children with keratoconus.MethodsThe study enrolled 64 patients aged 16 years or younger, each contributing one eye for a total of 64 eyes for analysis. Participants underwent an accelerated form of corneal cross-linking with 15 min of ultraviolet A irradiation at a rate of 7 mW/cm2, resulting in a cumulative energy dose of 5.4 J/cm2. The primary outcome measures were best corrected visual acuity (BCVA) and corneal tomography at 6 and 12 months post-intervention. Parameters assessed included BCVA, spherical and cylindrical refraction, keratometry (K1 and K2), maximum keratometry (Kmax) and thinnest corneal thickness (TCT). These metrics were documented preoperatively and then again at 6 and 12 months postoperatively. In addition, any ocular or systemic conditions related to keratoconus were recorded for each participant.ResultsThe results showed an improvement in BCVA at 12 months after surgery. K1 showed a decrease at both post-operative follow-ups while K2 remained constant throughout the observation period. Kmax showed a notable decrease at the 12 month postoperative follow-up. Although the TCT showed an initial decrease, it reached a stable state after 12 months of crosslinking. Refractive values remained stable at all subsequent examinations. Notably, no complications such as corneal opacity, non-healing epithelial defects or corneal infections occurred during the follow-up period. The most common ocular comorbidity was allergic conjunctivitis (34.4%).ConclusionThe findings suggest that accelerated corneal crosslinking treatment is effective in slowing or halting the progression of keratoconus. Furthermore, there were no persistent overt complications observed at 12 months after the procedure.en_US
dc.identifier.doi10.1007/s10792-024-02996-z
dc.identifier.issn0165-5701
dc.identifier.issn1573-2630
dc.identifier.issue1en_US
dc.identifier.pmid38342827en_US
dc.identifier.scopus2-s2.0-85184792677en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1007/s10792-024-02996-z
dc.identifier.urihttps://hdl.handle.net/11616/101812
dc.identifier.volume44en_US
dc.identifier.wosWOS:001166173600001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofInternational Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectKeratoconusen_US
dc.subjectCorneal crosslinkingen_US
dc.subjectPediatric patientsen_US
dc.titleOutcomes after corneal crosslinking treatment in paediatric patients with keratoconusen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu